The treatment of obesity has evolved significantly in recent years, and modern medicine today recognizes obesity as a chronic, multifactorial disease, which requires a complex therapeutic approach. Although lifestyle modifications – balanced nutrition and physical activity – represent the foundation of treatment, in certain situations these are not sufficient to achieve or maintain significant weight loss.
In these cases, pharmacological treatment for weight loss can represent a useful therapeutic option, integrated into a comprehensive medical program for obesity management.
What does pharmacological treatment for weight loss mean?
Pharmacological treatment for obesity includes medications that act on biological mechanisms involved in regulating body weight, such as:
- appetite regulation
- feeling of satiety
- energy metabolism
- glycemic control
These medications do not replace diet and physical activity, but complement them, facilitating weight loss and maintaining results in the long term.
When is pharmacological treatment indicated?
According to international guidelines, pharmacological treatment of obesity is indicated based on body mass index (BMI) and the presence of comorbidities.
1. Obesity (BMI ≥ 30 kg/m²)
Pharmacological treatment may be indicated in patients with:
BMI ≥ 30 kg/m²
In these situations, obesity is considered a disease in itself, and pharmacological interventions can be used when lifestyle modifications are not sufficient to achieve adequate weight loss.
2. Overweight with comorbidities (BMI ≥ 27 kg/m²)
Pharmacological treatment may also be indicated in patients with:
BMI ≥ 27 kg/m², if there is at least one condition associated with excess weight.
These comorbidities may include:
- type 2 diabetes mellitus
- arterial hypertension
- dyslipidemia
- obstructive sleep apnea
- cardiovascular disease
- metabolic fatty liver disease (fatty liver)
In these cases, weight loss can contribute significantly to reducing cardiovascular and metabolic risk.
Situations in which pharmacological treatment can be useful
In clinical practice, pharmacological treatment for obesity can be recommended in several situations.
Failure of lifestyle interventions
Many patients try different diets or weight loss programs without achieving lasting results.
The body has biological mechanisms that tend to maintain body weight, including:
- increased sensation of hunger after weight loss
- decreased energy expenditure
Medications for obesity can help with controlling these biological mechanisms.
Obesity associated with increased metabolic risk
In patients with obesity and cardiometabolic risk factors, weight loss can produce important benefits, such as:
- reduction in blood glucose
- decrease in blood pressure
- improvement in lipid profile
- reduction in abdominal circumference
Obesity associated with type 2 diabetes mellitus
In patients with type 2 diabetes mellitus, weight loss can significantly improve glycemic control.
Some medications used in obesity treatment also have favorable effects on carbohydrate metabolism.
What results can be achieved?
Weight loss achieved through pharmacological treatment varies depending on the medication used and the patient's characteristics.
In general, treatment can lead to:
- weight loss of 5–15% of body weight
- reduction in abdominal circumference
- improvement in metabolic profile
Even relatively modest weight loss of 5–10%, can have important health effects.
Obesity treatment – a long-term strategy
Obesity is a chronic disease, and its treatment should be viewed as a long-term process.
Effective management of obesity includes:
- complete medical evaluation
- lifestyle modifications
- nutritional and behavioral support
- pharmacological treatment, when indicated
- periodic medical monitoring
In some cases, in patients with severe obesity, bariatric surgery may also be considered.
Conclusion
Pharmacological treatment for weight loss can represent an effective option for patients with obesity or overweight associated with comorbidities, when lifestyle interventions are not sufficient.
The main indication is in patients with:
- BMI ≥ 30 kg/m², or
- BMI ≥ 27 kg/m² in the presence of conditions associated with excess weight.
Treatment must, however, be prescribed following a complete medical evaluation and integrated into a comprehensive obesity management strategy, tailored to each patient.
